Clinical Cancer Research, Vol 2, Issue 8 1397-1404, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases

NM Han, SA Curley and GE Gallick
Departments of Surgery and Tumor Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

pp60(c-src) and pp62(c-yes) are protein tyrosine kinases whose specific activities are increased in primary colorectal carcinomas. Activity of pp60(c-src) is further increased in colorectal liver metastases. This study was undertaken to compare pp60(c-src) and pp62(c-yes) expression and activity in human colorectal carcinoma liver metastases and to determine the potential prognostic significance of differences in activation of these two kinases. The pp60(c-src) and pp62(c-yes) tyrosine kinase activities and protein levels relative to those in normal colonic mucosa were determined using an immune complex kinase assay and immunoblot analysis in tissue specimens from 22 patients with primary colorectal carcinoma and synchronous metastatic liver disease and from 9 patients with metachronous colorectal carcinoma liver metastases. Of the primary colon tumors, 64% of the tumors contained elevated activities of both pp60(c-src) and pp62(c-yes). For liver metastases, however, only 10% had activation of both tyrosine kinases, 61% had elevated pp60(c-src) activity only, and 23% had elevated pp62(c-yes) activity only. Analysis of synchronous metastases from primary tumors with elevated activities in both kinases demonstrated that in 71% of these patients, the activity of either pp60(c-src) or pp62(c-yes) decreases relative to the primary tumor. Protein levels of pp60(c-src) and pp62(c-yes) in primary carcinomas and metastases remained unchanged from levels in normal colonic mucosa. These results demonstrate that differential regulation of the activities of pp60(c-src) and pp62(c-yes) occurs during tumor progression. Patients with either synchronous or metachronous liver metastases and elevated pp62(c-yes) kinase activity have biologically more aggressive disease and a worse prognosis than patients without elevated pp62(c-yes) activity in their liver metastases (median survival, 13 months versus 30 months, P < 0.005, Wilcoxon signed rank test). Analysis of patients with synchronous liver metastases also demonstrated a worse prognosis for those with elevated pp62(c-yes) kinase activity (P < 0.05, Wilcoxon signed rank test).

This article has been cited by other articles:

				S. Mathew, S. P. George, Y. Wang, M. R. Siddiqui, K. Srinivasan, L. Tan, and S. Khurana Potential Molecular Mechanism for c-Src Kinase-mediated Regulation of Intestinal Cell Migration J. Biol. Chem., August 15, 2008; 283(33): 22709 - 22722. [Abstract] [Full Text] [PDF]

				M. R. Stettner, W. Wang, L. B. Nabors, S. Bharara, D. C. Flynn, J. R. Grammer, G. Y. Gillespie, and C. L. Gladson Lyn Kinase Activity Is the Predominant Cellular Src Kinase Activity in Glioblastoma Tumor Cells Cancer Res., July 1, 2005; 65(13): 5535 - 5543. [Abstract] [Full Text] [PDF]

				Q. Ding, J. Stewart Jr., M. A. Olman, M. R. Klobe, and C. L. Gladson The Pattern of Enhancement of Src Kinase Activity on Platelet-derived Growth Factor Stimulation of Glioblastoma Cells Is Affected by the Integrin Engaged J. Biol. Chem., October 10, 2003; 278(41): 39882 - 39891. [Abstract] [Full Text] [PDF]

				A. D. Laird, G. Li, K. G. Moss, R. A. Blake, M. A. Broome, J. M. Cherrington, and D. B. Mendel Src Family Kinase Activity Is Required for Signal Tranducer and Activator of Transcription 3 and Focal Adhesion Kinase Phosphorylation and Vascular Endothelial Growth Factor Signaling in Vivo and for Anchorage-dependent and -independent Growth of Human Tumor Cells Mol. Cancer Ther., May 1, 2003; 2(5): 461 - 469. [Abstract] [Full Text] [PDF]

				D. Brown, U. Yallampalli, A. Owlia, and P. Singh pp60c-Src Kinase Mediates Growth Effects of the Full-Length Precursor Progastrin1-80 Peptide on Rat Intestinal Epithelial Cells, in Vitro Endocrinology, January 1, 2003; 144(1): 201 - 211. [Abstract] [Full Text] [PDF]

				H. S. Oh, H. Kwon, S. K. Sun, and C.-H. Yang QM, a Putative Tumor Suppressor, Regulates Proto-oncogene c-Yes J. Biol. Chem., September 20, 2002; 277(39): 36489 - 36498. [Abstract] [Full Text] [PDF]

				W. Wang, S. Marsh, J. Cassidy, and H. L. McLeod Pharmacogenomic Dissection of Resistance to Thymidylate Synthase Inhibitors Cancer Res., July 1, 2001; 61(14): 5505 - 5510. [Abstract] [Full Text] [PDF]